From: A study of 131iodine-labeling of histamine-indomethacin: its in vivo therapeutic effect and anti-tumor mechanisms in Lewis-bearing lung cancer
Groups
Tumor weight/g
Tumor volume
Tumor inhibitory rate(%)
Control
4.3±1.43
5.84±1.25
131I*
3.74±0.57
3.68±0.84
27.1*
IN
3.51±0.62
3.45±0.47
30.4
His-IN
3.48±0.79
3.61±0.34
34.5
131I-His-IN
2.79±0.41
2.08±0.63
54.8